BEGIN:VCALENDAR
PRODID:-//github.com/rianjs/ical.net//NONSGML ical.net 4.0//EN
VERSION:2.0
BEGIN:VEVENT
DESCRIPTION:After a 17-year hiatus in drug approvals for neurodegeneration
 \, disease-modifying drugs for AD have finally broken the ice. With Lecan
 emab's clinically proven 30% reduction in cognitive decline receiving the
  green light from the FDA and PMDA and Eli Lilly's Donanemab hot on their
  heels for approval\, 58 new trials entering the pipeline this year\, and
  the alpha-synuclein self-seeding assay changing the game for PD drug dev
 elopment.\n\nThe 12th Alzheimer's and Parkinson's Drug Development Summit
  is indisputably the ultimate industry-focused meeting dedicated to shari
 ng the hottest unpublished AD and PD research from senior biopharma KOLs 
 you won't hear anywhere else\, with deep-dive content all the way from ea
 rly discovery through to late phase trials and approvals.\n\nThis April\,
  join 150+ senior industry leaders across discovery\, preclinical\, bioma
 rker\, translational\, clinical\, and commercial this year from Eli Lilly
 \, Biogen\, Eisai\, Abbvie\, Merck\, Michael J. Fox Foundation\, Acumen\,
  Vigil Neuroscience\, and many more....\n\nTime: 9:00 AM - 5:00 PM\n
DTEND:20240425T170000
DTSTAMP:20260512T232257Z
DTSTART:20240423T090000
LOCATION:Hilton Boston Logan Airport\, One\, Hotel Drive\, Boston\, Massac
 husetts\, 02128\,
SEQUENCE:0
SUMMARY:After a 17-year hiatus in drug approvals for neurodegeneration\, d
 isease-modifying drugs for AD have finally broken the ice. With Lecanemab
 's clinic...
UID:5e82d3fa-395b-48bc-b653-9ace8ab5f534
END:VEVENT
END:VCALENDAR